Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Celadon Pharmaceuticals PLC ( (GB:CEL) ) has issued an update.
Celadon Pharmaceuticals Plc has announced its intention to seek shareholder approval for the cancellation of its Ordinary Shares from trading on AIM, effective 8 August 2025, and to re-register as a private limited company. This strategic move is considered by the company’s CEO to be in the best interest of the company and its shareholders, aiming to streamline operations and potentially enhance its market positioning. A general meeting is scheduled for 28 July 2025 to discuss these proposals, which, if approved, could impact shareholder trading opportunities and the company’s future operational structure.
More about Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company specializing in the development, production, and sale of cannabis-based medicines. The company focuses on improving the quality of life for chronic pain sufferers and exploring cannabis-based treatments for conditions like autism. It operates a large EU-GMP approved facility in the UK for cultivation, extraction, and research, and holds a Home Office license for commercial supply of pharmaceutical-grade cannabis products.
Average Trading Volume: 165,388
Technical Sentiment Signal: Sell
Current Market Cap: £7.92M
Find detailed analytics on CEL stock on TipRanks’ Stock Analysis page.